Referencer

Fra Rationel Farmakoterapi nr. 10 2006

1. Gerda Engholm, Hans H. Storm, Jacques Ferlay, Niels Christensen, Frøydis Langmark, Elínborg Ólafsdóttir, Eero Pukkala, Mats Talbäck (2005). NORDCAN: Cancer Incidence and Mortality in the Nordic Countries, Version 2.1. Danish Cancer Society.
2. Bernard-Marty C, Cardoso F, Piccart MJ. Facts and controversies in the systemic treatment of metastatic breast cancer. Oncologist 2004; 9:617-32.
3. Fumoleau I, Roché H, Kerbrat P, et al.Long-term cardiac toxicity after adjuvant epirubicin-based chemotherapy in early breast cancer: French Adjuvant Study Group results. Ann Oncol. 2006;17:85-92.
4. Praga C, Bergh J, Bliss J, et al. Risk of acute myeloid leukemia and myelodysplastic syndrome in trials of adjuvant epirubicin for early breast cancer: Correlation with doses of epirubicin and cyclophosphamide. J Clin Oncol 2005; 23:4179-91.
5. Early breast cancer trialist´s collaborative group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 365:1687-717.
6. Mouridsen HT, Robert NJ. The role of aromatase inhibitors as adjuvant therapy for early breast cancer in postmenopausal women. Eur J Cancer 2005;41:1678-89.
7. Cuzick J, Powles T, Veronesi U, Overview of the main outcomes in breast-cancer prevention trials. Lancet 2003;361(9354):296-300.
8. Mouridsen HT. Incidence and management of side effects associated with aromatase inhibitors in the adjuvant treatment of breast cancer in postmenopausal women. Current Medical Research and Opinion 2006 (in press).
9. Seidman  AD, Berry D, Cirrincione C. CALGB 9840: Phase III study of weekly (W) paclitaxel (P) via 1-hour(h) infusion versus standard (S) 3h infusion every third week in the treatment of metastatic breast cancer (MBC), with trastuzumab (T) for HER2-positive MBC and randomized for T in HER2 normal MBC. Proc Amer Soc Clin Oncol 2004, abstr. 512.
10. Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002; 20: 719-726.
11. Tan-Chiu E, Yothers G, Romond E, Geyer CE, Ewer M, et al. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J Clin Oncol (2005) 23: 7811-7819.
12. www.dbcg.dk (sidst besøgt 22.9.06).
13. Bria E, Nistico C, Cuppone F, et al. Benefit of taxanes as adjuvant chemotherapy for early breast cancer. Cancer 2006; published online 28 Apr 2006.
14. Slamon D, Eiermann W, Robert N, et al. Phase III randomised trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC-T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC-TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2 positive early breast cancer patients: BCIRG 006 study. Breast Cancer Res Treatment 2005;94 supplement 1:abstr 1.
15. Romond EH, Perez EA, Bryant J, Sumant VJ, Geyer CE, Davidson NE, et al.Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med (2005) 353: 1673-1684.
16. Piccart-Gebhart MJ, Procter MP, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, Gianni L, et al  for the HERA Study Team. A Randomized Trial of Trastuzumab following Adjuvant Chemotherapy in Women with HER2-Positive Breast Cancer. N Engl J Med (2005) 353: 1659-1672.
17. Giordano SH, Buzdar AU, Smith TL, et al. Is breast cancer survival improving? Trends in survival for patients with recurrent breast cancer diagnosed from 1974. Cancer 2004; 100:44-52.
18. Jones SE, Erban J, Overmoyer B, et al. Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. J Clin Oncol 2005; 23:5542-51.
19. Ejlertsen B, Pfeiffer P, Pdersen D, et al. Decreased efficacy of cyclophosphamide, epirubicin and 5-fluorouracil in metastatic breast cancer when reducing treatment duration from 18 to 6 months. Eur J Cancer. 1993;29A:527-31.
    20. 
20. Ghersi D, Wilcken N, Simes J. A systematic review of taxane-containing regimens for metastatic breast cancer. Br J Cancer 2005;93:293-301.
21. Crown J, Dieras V, Kaufmann M, et al. Chemotherapy for metastatic breast cancer – report of a European expert panel. Lancet Oncology 2002;3:719-27.
22. Ejlertsen B, Mouridsen H. Bør kemoterapi eller endokrin terapi anvendes først hos patienter med fremskreden brystkræft. Ugeskr Laeger 2004;166:2434.
23. Mouridsen HT, Gershanovich M. The role of aromatase inhibitors in the treatment of metastatic breast cancer. Seminars in Oncol 2003; 30, Suppl 14:33-45.
24. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy and a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2002; 344: 783-792.
25. Marty M, Cognetti F, Maraninchi D, at al. Efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first line treatment: results of a randomized phase II trial by the M77001 study group. J Clin Oncol 2005; 23:4265-74.